http://www.marketwire.com Marketwired en Copyright: (C) Marketwired 1 http://www.marketwire.com/rss/marketwire_logo.jpg http://www.marketwire.com
Continued advancement for expansion into nutraceutical market
Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q4 2017
Encouraging preliminary data from bio-efficacy study evaluating avenanthramides in exercise-induced inflammation warrant extension to evaluate additional biomarkers
EDMONTON, ALBERTA–(Marketwired – Aug. 18, 2017) – Ceapro Inc. (TSX VENTURE:CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30, 2017 and provided an overview of recent operational highlights.
Financial Highlights for the Second Quarter 2017
- Total sales of $3,173,000 for the quarter ended June 30, 2017 compared to $4,168,000 in Q2 2016;
- Gross margin of $2,018,000 for the quarter ended June 30, 2017 compared to $3,014,000 in Q2 2016;
- Income from operations of $1,004,000 for the quarter ended June 30, 2017 compared to $2,501,000 in Q2 2016; and
- Net profit after tax of $370,000 for the quarter ended June 30, 2017 compared to $1,636,000 in Q2 2016.
“This positive past quarter was highlighted by continued investments in our technologies as well as accelerated R&D investments in our product pipeline as a step toward our long-term goal of transforming Ceapro from a manufacturing company to a full-fledged biopharmaceutical company. On a short-term basis, we are working to maintain and expand our base business in cosmeceuticals, which provides us with the financial security to position ourselves for our contemplated transition into large potential markets in nutraceuticals and pharmaceuticals with our value drivers avenanthramides and beta glucan,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro “Over the course of 2017 we have been assessing different marketing scenarios with the intention of increasing our market share in cosmeceuticals and restoring the market for beta glucan, which has been mainly responsible for the difference in sales observed between the first six months of 2017 and 2016. New applications and market channels are being developed.”
“Additionally, we expect to see continued growth in our avenanthramides program as we anticipate new products to be launched by major customers over the next twelve months utilizing our avenanthramides in variety of products, mostly in haircare. We also keep our eyes and ears open for any potential and affordable accretive acquisition to accelerate our entry into the nutraceuticals market,” Mr. Gagnon added.
Beta Glucan Program Highlights
Ceapro’s research program for the development of beta glucan as an active ingredient in functional food/drink and nutraceuticals is progressing very well.
The Company previously announced positive results for the first development phase of a functional drink related to the physicochemical properties of a newly formed chemical complex of beta glucan impregnated with Co-enzyme Q10 (iBg-CoQ10). These results were presented by Dr. Feral Temelli at Lisbon Conference on supercritical fluids in April 2017 and a manuscript is being submitted for scientific publication.
The positive results were obtained from the functional drink project, first resulting in the successful development of a novel water soluble chemical complex (CoQ10-Beta Glucan) by the utilization of Ceapro’s PGX technology, and secondly the successful preparation of an appealing prototype beverage formulation that was determined to be well liked by a trained panel composed of 98 subjects.
The Company’s next step is to assess improved bioavailability of the new chemical complex (iBg-CoQ10) compared to commercially available CoQ10. Ceapro expects results from animal studies during Q4 2017.
Avenanthramides Program Highlights
The Company’s ongoing clinical study assessing avenanthramides as an anti-inflammation product is underway. Ceapro has just obtained encouraging preliminary topline results, which the Company believes warrants an extension of the study to assess additional sophisticated biomarkers potentially involved in inflammation. The Company expects final results by year end. This study could support the launch of avenanthramides as an active ingredient for functional food to be sold by major players in the food industry.
PGX Enabling Technology Update
The Company announced the completion of its pilot scale facility for its proprietary PGX enabling technology. Installation of custom designed process equipment in the facility has also been completed. Ceapro has formed an expert PGX team to work with the resulting technology platform, which will enable the development of new patentable chemical complexes. The Company has signed an agreement with the University of Alberta (“U of A”) to develop at least ten new chemical entities (“NCEs”) over the next two years. Physicochemical properties of these NCEs will be tested at U of A, as well as their potential applications in various healthcare sectors. The PGX technology is then a key asset that will enable the transition of Ceapro into a biopharmaceutical company.
Financial Results for the Three and Six-Month Periods Ended June 30, 2017
- Total sales of $3,173,00 in Q2 2017 and $6,357,000 in H1 2017 respectively, compared to $4,168,000 and 8,231,000 in 2016 due to a decrease of sales of beta glucan.
- Net profit after tax of $370,000 in Q2 2017 and $388,000 in H1 2017 compared to $1,636,000 and $2,849,000 in 2016. Net profit is affected by an increase of a non-cash item of $396,000 related to the grant of stock options in January 2017.
- Research and Development investments net of grants of $301,000 in Q2 2017 and $897,000 in H1, 2017 respectively compared to $61,000 and $267,000 in 2016. The increase relates to additional investments to develop our technologies and expand the product pipelines for our value driver active ingredients and also relates to the timing of recognition of scientific research and development tax credits.
- General and Administration expenses of $687,000 in Q2 2017 and $1,526,000 in H1 2017 respectively compared to $525,000 and $1,021,000 in 2016. The increase in G&A is primarily due to an increase in salaries and benefits expense relating to the granting of stock options in January 2017 which resulted in an increase in share-based payments in H1 2017 of approximately $360,000 compared to H1 2016, an increase in management consulting fees, and an increase in public company regulatory, filing and publication fees. While the share based payment accounting charge impacts net income, it has no impact on cash flows.
- Sales and Marketing expenses of $5,000 in Q2 2017 and $9,000 in H1 2017 compared to $600 and $2,800 in 2016. Marketing expenses are negligible due to a current sales strategy of sales only through a distribution network, which is being revisited.
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for healthcare and cosmetic industries utilizing the Company’s proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
|Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash and cash equivalents||7,079,371||9,150,035|
|Inventories (note 4)||1,368,231||1,183,428|
|Prepaid expenses and deposits||725,256||371,950|
|Investment tax credits receivable||487,339||487,339|
|Licences (note 5)||28,885||30,366|
|Property and equipment (note 6)||15,738,661||14,324,887|
|Deferred tax assets||–||64,208|
|LIABILITIES AND EQUITY|
|Accounts payable and accrued liabilities||749,774||969,234|
|Deferred revenue (note 8)||188,016||489,613|
|Current portion of long-term debt (note 7)||1,132,533||1,002,246|
|Current portion of CAAP loan (note 10)||77,858||72,942|
|Long-term debt (note 7)||659,127||1,255,658|
|CAAP loan (note 10)||217,534||201,233|
|Deferred tax liabilities||325,905||–|
|Share capital (note 9 (b))||15,516,578||14,859,136|
|Contributed surplus (note 9 (f))||4,101,528||3,874,725|
|TOTAL LIABILITIES AND EQUITY||27,023,890||26,391,634|
|Consolidated Statements of Net Income and Comprehensive Income|
|Quarters Ended June 30,||Six Months Ended June 30,|
|Revenue (note 14)||3,173,225||4,167,855||6,356,735||8,231,431|
|Cost of goods sold||1,155,231||1,153,517||2,627,555||2,383,280|
|Research and product development||301,138||(61,251||)||897,162||266,581|
|General and administration||686,686||524,858||1,526,026||1,020,504|
|Sales and marketing||4,727||643||9,017||2,829|
|Finance costs (note 13)||21,711||48,896||100,176||147,377|
|Income from operations||1,003,732||2,501,192||1,196,799||4,410,860|
|Other operating loss (note 12)||(246,797||)||(143,587||)||(427,840||)||(319,279||)|
|Income before tax||756,935||2,357,605||768,959||4,091,581|
|Current tax (expense) recovery||–||36,090||9,344||(421,916||)|
|Deferred tax (expense) recovery||(386,513||)||(757,897||)||(390,113||)||(820,475||)|
|Income tax (expense) recovery||(386,513||)||(721,807||)||(380,769||)||(1,242,391||)|
|Total comprehensive income for the period||370,422||1,635,798||388,190||2,849,190|
|Net income per common share (note 19):|
|Weighted average number of common shares outstanding (note 19):|